Shire plc announced that a Phase 3b study found adults with attention deficit hyperactivity disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.
Clavis Pharma and its partner Clovis Oncology, Inc. announce that the first two patients have been recruited into a Phase 2 clinical study comparing CP-4126 gemcitabine in the treatment of patients with pancreatic cancer.
Studies by a Purdue University-led team have revealed a potential marker for prostate cancer that could be the starting point for less invasive testing and improved diagnosis of the disease.
Scientists at the Gladstone Institute of Cardiovascular Disease have found a new way to make beating heart cells from the body’s own cells that could help regenerate damaged hearts.
Thermo Fisher Scientific Inc. has extended its state-of-the-art manufacturing capability in Shanghai, China, for the production of Nunc Cell Factory single-use, certified-sterile bioprocessing systems.
The Omni LH96 Homogenizer Workstation is designed for walk-away batch processing of up to 192 samples. It consists of a core processing platform that can be enhanced with a broad range of user specified modules.
Danish drug maker Novo Nordisk A/S reported a 19% increase in net profit for the second quarter and raised its outlook, citing strong sales of its modern insulin products.
Sigma-Aldrich announced an agreement with the National Heart, Lung, and Blood Institute and Boston University to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease using plasma samples from the Framingham Heart Study.
BrainCells Inc. announced that it has signed an agreement with Proximagen Group to acquire sabcomeline, a clinical-stage muscarinic partial agonist that has potential in the treatment of various psychiatric and neurologic disorders.
Detailed pictures reveal how an experimental antibiotic can kill bacteria that are already resistant to existing treatments. The findings could ultimately help scientists to develop new antibiotics to tackle the bacteria responsible for many infections.
Clinical trials from two international research teams have shown that icatibant, a new drug that blocks the action of an inflammatory protein known as bradykinin, is safe and effective in treating acute attacks of hereditary angioedema.
A newly described metabolic pathway used by malaria-causing parasites may help them survive inside human blood cells. The finding clarifies the picture of parasite metabolism and provides clues to potential weak points in the pathway that might be attacked with drugs.
Researchers are some of the first to prove that a gene linked to a disease trait by genome wide association studies can be clinically relevant and an important determinant of disease risk.
Computer scientists and biochemists at the University of Washington two years ago launched an ambitious project harnessing the brainpower of computer gamers to solve medical problems.